TRILLIUM

Serial Number 98804622
Registration 7825760
700

Registration Progress

Application Filed
Oct 16, 2024
Under Examination
Approved for Publication
Apr 22, 2025
Published for Opposition
Apr 22, 2025
Registered
Jun 10, 2025

Trademark Image

TRILLIUM

Basic Information

Serial Number
98804622
Registration Number
7825760
Filing Date
October 16, 2024
Registration Date
June 10, 2025
Published for Opposition
April 22, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Jun 10, 2025
Registration
Registered
Classes
005

Rights Holder

Ratio Therapeutics, Inc.

03
Address
One Design Center Place, Ste 19-601
Boston, MA 02210

Ownership History

Ratio Therapeutics, Inc.

Original Applicant
03
Boston, MA

Ratio Therapeutics, Inc.

Owner at Publication
03
Boston, MA

Ratio Therapeutics, Inc.

Original Registrant
03
Boston, MA

Legal Representation

Attorney
Nicole Gage

USPTO Deadlines

Next Deadline
2053 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2025-06-10)
Due Date
June 10, 2031
Grace Period Ends
December 10, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

9 events
Date Code Type Description Documents
Jun 10, 2025 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED Loading...
Jun 10, 2025 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Apr 22, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Apr 22, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 16, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Mar 27, 2025 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Mar 24, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 16, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 16, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Radio-pharmaceutical preparations for the diagnosis and treatment of cancers; radio-pharmaceutical preparations for the purpose of increasing the effectiveness of other pharmaceutical products in the treatment of cancers; pharmaceutical agents that deliver a range of radioisotopes for therapeutic or diagnostic use
First Use Anywhere: May 31, 2023
First Use in Commerce: May 31, 2023

Classification

International Classes
005